Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

JNJ Q1 FY2026

Johnson & Johnson reported results for its fiscal first quarter ended March 29, 2026, with contributions from Innovative Medicine and MedTech and an outlook centered on portfolio growth, pipeline execution, and operational investment.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products.
  • Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth.
  • Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Risks that still need monitoring

  • Talc litigation

    Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts.

  • Exclusivity and pricing pressure

    Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines.

  • Clinical and regulatory execution

    Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

Primary sources

Johnson & Johnson 2026 First-Quarter ResultsJohnson & Johnson · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/14/2026, 10:45:00 AM

Open original source
Johnson & Johnson Investor RelationsJohnson & Johnson · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Johnson & Johnson Form 10-Q for the fiscal quarter ended March 29, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/22/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research